featured
Prognostic Impact of Circulating Tumor DNA Status Post Allogeneic HSCT in AML and MDS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Prognostic Impact of Circulating Tumor DNA Status Post-Allogeneic Hematopoietic Stem Cell Transplantation in AML and MDS
Blood 2019 Jun 20;133(25)2682-2695, S Nakamura, K Yokoyama, E Shimizu, N Yusa, K Kondoh, M Ogawa, T Takei, A Kobayashi, M Ito, M Isobe, T Konuma, S Kato, R Kasajima, Y Wada, T Nagamura-Inoue, R Yamaguchi, S Takahashi, S Imoto, S Miyano, A TojoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.